



medlab

MEDLAB CLINICAL LIMITED

ABN: 51 169 149 071

APPENDIX 4D (RULE 4.2A3)

HALF-YEAR REPORT

FOR THE PERIOD ENDED 31 DECEMBER 2017

RESULTS FOR ANNOUNCEMENT TO THE MARKET

CURRENT REPORTING PERIOD:
PREVIOUS CORRESPONDING PERIOD:

Half-Year Ended 31 December 2017
Half-Year Ended 31 December 2016

KEY INFORMATION	Amount \$	Up/Down	Movement
Revenue from ordinary operations			
Sale of goods (nutraceutical business)	1,961,821	up	32.3%
Other revenue	475,415	Down	25.8%
Total revenue from ordinary operations	2,437,236	up	14.8%
Loss from ordinary activities after tax attributable to members of the company	(2,269,323)	up	33.1%
Net loss after tax attributable to members of the company	(2,269,323)	up	33.1%

No dividends have been proposed during the period

	31 December 2017 \$	31 December 2016 \$
Net tangible assets per security	0.008	0.029

This report should be read in conjunction with the consolidated financial report of Medlab Clinical Limited for the half-year ended 31 December 2017 which were subject to a review by ESV Accounting and Business Advisors. The review report is attached part of the Interim Report.



Sean Hall
Managing Director
Dated this 28th day of February 2018